TABLE 6

Effects of Changes in Therapy and Neonatal Risk Factors Between Period I and Period II on Outcomes for Gestational Age-Specific Cohort (<28 Weeks of Gestation)

Odds Ratio (95% Confidence Interval)
MDI of <70Neurosensory AbnormalityaNeurodevelopmental Impairmentb
Period (I versus II)1.73 (0.83–3.64)0.63 (0.25–1.59)1.75 (0.81–3.77)
Maternal education less than high school1.92 (0.88–4.20)0.84 (0.30–2.37)1.35 (0.60–3.03)
Race1.57 (0.84–2.94)1.43 (0.76–2.70)
Gender1.28 (0.71–2.32)1.05 (0.57–1.92)
Multiple birth1.99 (0.87–4.52)1.81 (0.69–4.79)2.28 (0.98–5.29)
Prenatal steroid therapy0.56 (0.28–1.12)0.79 (0.34–1.82)0.50 (0.24–1.04)
Duration of ventilator dependence1.02 (1.01–1.03)c1.01 (0.995–1.025)1.02 (1.01–1.04)c
Severe cranial ultrasound abnormalityd2.18 (1.02–4.65)e7.67 (3.46–17.00)f4.53 (1.94–10.58)f
Indomethacin0.59 (0.30–1.17)1.35 (0.58–3.13)0.62 (0.31–1.26)
Ligation of PDA1.66 (0.85–3.22)1.39 (0.63–3.03)2.04 (1.03–4.04)e
Postnatal steroid therapy1.90 (0.91–3.98)2.69 (1.08–6.68)e2.73 (1.28–5.85)e
  • a Cerebral palsy, blindness, or deafness.

  • b MDI of <70 and/or neurosensory abnormality.

  • c P < .01.

  • d Including grade III or IV bleeding, periventricular hemorrhage, or ventricular dilation at discharge.

  • e P < .05.

  • f P < .001.